Amgen (AMGN): Phase 3 romosozumab Answers Some Questions - BMO
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
BMO Capital analyst, Ian Somaiya, reiterated his Outperform rating Amgen (NASDAQ: AMGN) after Amgen released additional results from its Phase 3 study of romosozumab, which provided a tangible explanation for the trial not achieving a key secondary endpoint of reduction in non-vertebral fractures. A lack of visibility into how this will translate into a label claim and compelling data for Radius's abaloparatide could limit peak sales to $700mn (assuming 1.0% peak global market share).
Looking ahead, the analyst sees the FOURIER CV outcomes trial (data 1Q17) as the most important catalyst for AMGN shares. No change to the price target of $190.
Shares of Amgen closed at $171.38 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Amgen (AMGN) Makes Investment in Israel-Based eHealth Ventures
- UPDATE: Stifel Upgrades Legacy Reserves (LGCY) to Hold
- Stifel Remains Sidelined on Crane Co. (CR) Following Earnings Call
Create E-mail Alert Related CategoriesAnalyst Comments
Related EntitiesBMO Capital
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!